MXPA03010007A - USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA. - Google Patents

USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.

Info

Publication number
MXPA03010007A
MXPA03010007A MXPA03010007A MXPA03010007A MXPA03010007A MX PA03010007 A MXPA03010007 A MX PA03010007A MX PA03010007 A MXPA03010007 A MX PA03010007A MX PA03010007 A MXPA03010007 A MX PA03010007A MX PA03010007 A MXPA03010007 A MX PA03010007A
Authority
MX
Mexico
Prior art keywords
bisphosphonates
pharmaceutical uses
pharmaceutical
Prior art date
Application number
MXPA03010007A
Other languages
English (en)
Inventor
John J Seaman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA03010007A publication Critical patent/MXPA03010007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MXPA03010007A 2001-05-02 2002-04-30 USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA. MXPA03010007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28822001P 2001-05-02 2001-05-02
PCT/EP2002/004771 WO2002087555A2 (en) 2001-05-02 2002-04-30 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer

Publications (1)

Publication Number Publication Date
MXPA03010007A true MXPA03010007A (es) 2004-02-12

Family

ID=23106248

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010007A MXPA03010007A (es) 2001-05-02 2002-04-30 USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.

Country Status (22)

Country Link
US (1) US20040157799A1 (es)
EP (1) EP1418897A2 (es)
JP (1) JP2004528340A (es)
KR (1) KR20040015230A (es)
CN (1) CN1277545C (es)
AR (1) AR033175A1 (es)
AU (1) AU2002257802B2 (es)
BR (1) BR0209365A (es)
CA (1) CA2443625A1 (es)
CZ (1) CZ20032950A3 (es)
HK (1) HK1080711A1 (es)
HU (1) HUP0400096A2 (es)
IL (1) IL158273A0 (es)
MX (1) MXPA03010007A (es)
MY (1) MY141584A (es)
NO (1) NO20034877L (es)
NZ (1) NZ528676A (es)
PL (1) PL363507A1 (es)
RU (1) RU2297229C2 (es)
SK (1) SK13512003A3 (es)
WO (1) WO2002087555A2 (es)
ZA (1) ZA200307666B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CA2525929A1 (en) * 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
RU2407746C2 (ru) * 2008-09-29 2010-12-27 ЗАО "Фарм-Синтез" Радиофармацевтическое средство для диагностики и лечения (терапии) костных поражений скелета и способ его получения
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP3295935B1 (en) 2009-07-31 2020-07-22 Grünenthal GmbH Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2289900A1 (en) * 2009-08-26 2011-03-02 Humboldt Universität zu Berlin Bisphosphonates as inhibitors of acid sphingomyelinase
HUE025737T2 (en) * 2009-09-01 2016-05-30 Univ Duke Bisphosphonate compositions and methods for treating heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
WO2015060924A1 (en) * 2013-10-25 2015-04-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US9688765B2 (en) 2014-06-11 2017-06-27 Antecip Bioventures Ii Llc Methods using RANK/RANKL antagonist antibodies for treating pain
JO3394B1 (ar) * 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
AU2015317409A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
US10408818B2 (en) * 2014-11-27 2019-09-10 Koninklijke Philips N.V. Chemical analysis of urine and feces vapor
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN108514645B (zh) * 2018-04-08 2021-07-20 西南医科大学附属医院 一种兼具骨显像和骨转移瘤治疗的制剂及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
FI89364C (fi) * 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
EP0805673A1 (en) * 1994-10-20 1997-11-12 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6142383A (en) * 1998-04-08 2000-11-07 Hinsilblon Laboratories Method of waterless large scale dispersion of essential oils and apparatus therefor
EP1131100B1 (en) * 1999-01-15 2003-03-12 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases comprising a photosensitizer and a bisphosphonate
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis

Also Published As

Publication number Publication date
CN1277545C (zh) 2006-10-04
WO2002087555A3 (en) 2004-02-05
JP2004528340A (ja) 2004-09-16
IL158273A0 (en) 2004-05-12
SK13512003A3 (sk) 2004-08-03
HUP0400096A2 (hu) 2004-04-28
CZ20032950A3 (cs) 2004-06-16
MY141584A (en) 2010-05-14
RU2003133773A (ru) 2005-02-10
AU2002257802B2 (en) 2006-02-16
NO20034877L (no) 2003-12-19
PL363507A1 (en) 2004-11-29
EP1418897A2 (en) 2004-05-19
ZA200307666B (en) 2004-05-05
WO2002087555A2 (en) 2002-11-07
AR033175A1 (es) 2003-12-03
RU2297229C2 (ru) 2007-04-20
US20040157799A1 (en) 2004-08-12
KR20040015230A (ko) 2004-02-18
BR0209365A (pt) 2004-06-08
CN1638778A (zh) 2005-07-13
NO20034877D0 (no) 2003-10-31
CA2443625A1 (en) 2002-11-07
NZ528676A (en) 2006-03-31
HK1080711A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
MXPA03010007A (es) USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
MXPA03006775A (es) Formulacion farmaceutica.
MXPA03007215A (es) Formulaciones farmaceuticas.
MXPA03007641A (es) Formulacion farmaceutica.
GB0104534D0 (en) Pharmaceutical combination
PL366510A1 (en) Pharmaceutical combinations
GB0101225D0 (en) Pharmaceutical compounds
GB0101227D0 (en) Pharmaceutical compounds
GB0124523D0 (en) Pharmaceutical combination
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
GB0129872D0 (en) Novel pharmaceutical
GB0129395D0 (en) Pharmaceutical combination
ZA200110500B (en) Pharmaceutical composition.
MXPA03007318A (es) Composicion farmaceutica.
AU2002342940A8 (en) New pharmaceutical compounds
ZA200110501B (en) Pharmaceutical composition.
GB0130509D0 (en) Novel pharmaceutical
GB0129876D0 (en) Novel pharmaceutical
GB0130510D0 (en) Novel pharmaceutical
GB0130511D0 (en) Novel pharmaceutical
ZA200402731B (en) Pharmaceutical formulation.
ZA200110499B (en) Pharmaceutical composition.
GB0129871D0 (en) Novel pharmaceutical
GB0118186D0 (en) Medicine invention

Legal Events

Date Code Title Description
FA Abandonment or withdrawal